HGF and pulmonary arterial hypertension: Future studies are needed to determine if enhanced expression of SOX17 or inhibition of its downstream targets such as RUNX1, HGF/c-Met, or E2F1 can reverse PAH associated with the rare or common variants of SOX17 mutations or in patients with PAH that are not associated with impaired SOX17 expression.